within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P02B_Antitrematodals.P02BX02_Niridazole;

model Niridazole
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 2.7777777777777776e-07,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Niridazole</td></tr><tr><td>ATC code:</td><td>P02BX02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>25</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Niridazole is an antiparasitic medication belonging to the nitrothiazole class, previously used primarily for the treatment of schistosomiasis (bilharziasis). Its use has largely been discontinued due to toxicity concerns and the availability of safer alternatives. It is not a currently approved treatment in most countries.</p><h4>Pharmacokinetics</h4><p>No recent or primary sources report pharmacokinetic parameters in humans; parameter estimates provided here are based on limited information from older literature summaries and general pharmacokinetic principles. Estimates provided are for adults following oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.P.P02BX02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Niridazole;
